Mesoblast Limited
MESO
$14.99
-$0.09-0.60%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
5/12/2026
-
Tickeron - Stocks
5/1/2026
-
TipRanks Financial Blog
4/30/2026
-
SeekingAlpha.com: All News
Mesoblast (MESO, $15.56) entered Downtrend as Momentum indicator drops below 0 level on Apr 29, 2026
4/30/2026
-
Tickeron - Stocks
4/30/2026
-
Tickeron - Stocks
4/30/2026
-
Globe Newswire
4/29/2026
-
Globe Newswire
4/28/2026
-
Yahoo! Finance: News
4/27/2026
-
Insider Monkey
4/24/2026
-
Tickeron - Stocks
4/23/2026
-
MarketBeat
4/19/2026
-
Insider Monkey
4/19/2026
-
Yahoo! Finance: News
4/18/2026
-
Insider Monkey
4/18/2026
-
Insider Monkey
4/16/2026
-
Tickeron - Technical Analysis
4/16/2026
-
Nasdaq News: Stocks
4/15/2026
-
TipRanks Financial Blog
4/15/2026
-
MarketBeat
4/15/2026
-
TipRanks Financial Blog
4/15/2026
-
Seeking Alpha - Healthcare
4/15/2026
-
Nasdaq News: Markets
4/15/2026
-
Globe Newswire
4/14/2026
-
TipRanks Financial Blog
4/14/2026
-
TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, February 26, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of Aug 24 and 28 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
61 3 9639 6036
Address
55 Collins Street
Melbourne, VIC 3000
Melbourne, VIC 3000
Country
Year Founded
Business Description
Sector
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company’s...
more